BioCentury | Jan 31, 2020
Distillery Therapeutics

FERMT2 identified as target in renal fibrosis

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the focal adhesion molecule FERMT2 could treat renal fibrosis. In renal tissue from patients with renal fibrosis, FERMT2 levels were higher in fibrotic tissue than in normal tissue....
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...
BC Extra | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Depleting platelets of inhibiting SOCS3 for atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Platelet depletion or inhibition of SOCS3, a platelet-induced regulator of macrophage polarization, could treat atherosclerosis. Blood levels of SOCS3 RNA were higher in 61 women presenting with myocardial infarction (MI)...
BC Innovations | Dec 17, 2019
Distillery Therapeutics

Inhibiting tankyrase to treat osteoarthritis and regenerate cartilage

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Combined TNKS and TNKS2 inhibition could treat osteoarthritis, which features progressive cartilage degeneration, and enhance the efficacy of stem cell-based therapies for cartilage regeneration. In osteoarthritis patients, TNKS and...
BC Innovations | Dec 12, 2019
Tools & Techniques

New hepatic stellate cell subset drives liver fibrosis

A team including University of Edinburgh and Gilead researchers has used single-cell sequencing to zero in on a pathogenic subpopulation of hepatic stellate cells that could be targeted to treat liver fibrosis. Reported in a...
BC Innovations | Nov 27, 2019
Product Development

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone...
BC Innovations | Nov 22, 2019
Distillery Therapeutics

Dopamine receptor agonism for pulmonary fibrosis, liver fibrosis

DISEASE CATEGORY: Pulmonary; hepatic INDICATION: Pulmonary fibrosis; liver fibrosis Agonism of the dopamine receptor DRD1 could treat pulmonary and liver fibrosis. In cultures of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis (IPF), a...
BC Innovations | Oct 28, 2019
Distillery Therapeutics

Enleofen co-founders identify IL-11 as pulmonary fibrosis target

DISEASE CATEGORY: Pulmonary INDICATION: Pulmonary fibrosis A National Heart Centre Singapore team led by Enleofen Bio Pte. Ltd. co-founders Stuart Cook and Sebastian Schafer showed that inhibiting IL-11 could treat pulmonary fibrosis. Levels of IL-11...
Items per page:
1 - 10 of 1115